LeMaitre Vascular (LMAT) Projected to Post Quarterly Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect LeMaitre Vascular to post earnings of $0.50 per share and revenue of $57.61 million for the quarter. LeMaitre Vascular has set its FY 2025 guidance at 2.150-2.320 EPS and its Q1 2025 guidance at 0.480-0.530 EPS.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts' consensus estimates of $0.49. The business had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Trading Down 0.2 %

NASDAQ LMAT traded down $0.15 during trading on Friday, reaching $91.61. The company's stock had a trading volume of 106,920 shares, compared to its average volume of 161,776. The firm has a 50 day moving average price of $86.90 and a 200 day moving average price of $93.42. LeMaitre Vascular has a 12 month low of $64.44 and a 12 month high of $109.58. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of 50.06, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.87%. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular's payout ratio is presently 41.24%.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company's stock, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 10.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LMAT. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.